Epstein-Barr virus latent membrane protein 1 activates nuclear factor-κB in human endothelial cells and inhibits apoptosis

Transplantation

Volumn 78, Issue 1, 2004, Pages 41-49

  Xiong, Anming ^a   Clarke Katzenberg, Regina H ^a   Valenzuela, Glenn ^a   Izumi, Kenneth M ^b   Millan, Maria T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Apoptosis; Endothelial cell activation; Epstein Barr virus; Latent membrane protein 1; NF B

Indexed keywords

CASPASE 3; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; LATENT MEMBRANE PROTEIN 1; PROTEIN BCL 2; RANTES; VASCULAR CELL ADHESION MOLECULE 1;

A1 GENE; ALLOGRAFT; APOPTOSIS; ARTICLE; C IAP2 GENE; CELL ACTIVATION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENDOTHELIUM CELL; EPSTEIN BARR VIRUS; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INCIDENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRAF1 GENE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VIRUS INFECTION;

APOPTOSIS; CELLS, CULTURED; CHEMOKINES; CYTOKINES; ENDOTHELIUM, VASCULAR; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; NF-KAPPA B; PROTEIN STRUCTURE, TERTIARY; PROTEINS; RETROVIRIDAE; TNF RECEPTOR-ASSOCIATED FACTOR 1; TRANSFECTION; UMBILICAL VEINS; VIRAL MATRIX PROTEINS;

EID: 4143054908     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000129805.02631.EF     Document Type: Article

References (30)

1. Lautenschlager I, Hockerstedt K, Jalanko H, et al. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997; 25(1): 190.
2. Kloover JS, Soots AP, Krogerus LA, et al. Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1, vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 2000; 69(12): 2641.
3. Streblow DN, Kreklywich C, Yin Q, et al. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Virol 2003; 77(3): 2182.
4. Hurwitz M, Desai DM, Cox KL, et al. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 2004; 8: 267.
5. Millan MT, Natkunam Y, Clarke-Katzenberg R, et al. Epstein-Barr virus infection is associated with endothelial Bcl-2 expression in transplant liver allografts. Transplantation 2002; 73(3): 465.
6. Badrichani AZ, Stroka DM, Bilbao G, et al. Bcl-2 and Bel-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-kappaB. J Clin Invest 1999; 103(4): 543.
7. Hancock WW, Buelow R, Sayegh MH, et al. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998; 4(12): 1392.
8. Jones K, Rivera C, Sgadari C, et al. Infection of human endothelial cells with Epstein-Barr virus. J Exp Med 1995; 182(5): 1213.
9. Holmgren L, Szeles A, Rajnavolgyi E, et al. Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood 1999; 93(11): 3956.
10. Izumi KM, Cahir McFarland ED, Ting AT, et al. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol 1999; 19(8): 5759.
11. Devergne O, Cahir McFarland ED, Mosialos G, et al. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998; 72(10): 7900.
12. Pear WS, Nolan GP, Scott ML, et al. Production of high-liter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90(18): 8392.
13. Dyer RB, Herzog NK. Isolation of intact nuclei for nuclear extract preparation from a fragile B-lymphocyte cell line. Biotechniques 1995; 19(2): 192.
14. Jakel KT, Loning T, Arndt R, et al. Rejection, herpesvirus infection, and Ki-67 expression in endomyocardial biopsy specimens from heart transplant recipients. Pathol Res Pract 188 (1-2):27, 1992.
15. Shi Y, Tokunaga O. Herpesvirus (HSV-1, EBV and CMV) infections in atherosclerotic compared with non-atherosclerotic aortic tissue. Pathol Int 2002; 52(1): 31.
16. Horvath R, Cerny J, Benedik J Jr, et al. The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. J Clin Virol 2000; 16(1): 17.
17. Denton MD, Davis SF, Baum MA, et al. The role of the graft endothelium in transplant rejection: evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection. Pediatr Transplant 2000; 4(4): 252.
18. Hoffmann MW, Wonigeit K, Steinhoff G, et al. Production of cytokines (TNF-alpha, IL-1-beta) and endothelial cell activation in human liver allograft rejection. Transplantation 1993; 55(2): 329.
19. Xu B, Sakkas LI, Slachta CA, et al. Apoptosis in chronic rejection of human cardiac allografts. Transplantation 2001; 71(8): 1137.
20. Sixbey JW, Vesterinen EH, Nedrud JG, et al. Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 1983; 306(2): 480.
21. Csizmadia V, Gao W, Hancock SA, et al. Differential NF-kappaB and IkappaB gene expression during development of cardiac allograft rejection versus CD154 monoclonal antibody-induced tolerance. Transplantation 2001; 71(7): 835.
22. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3(3): 221.
23. Willuweit A, Sass G, Schoneberg A, et al. Chronic inflammation and protection from acute hepatitis in transgenic mice expressing TNF in endothelial cells. J Immunol 2001; 167(7): 3944.
24. Mosialos G. Cytokine signaling and Epstein-Barr virus-mediated cell transformation. Cytokine Growth Factor Rev 2001; 12(2-3): 259.
25. Waxman AB, Mahboubi K, Knickelbein RG, et al. Interleukin-11 and interleukin-6 protect cultured human endothelial cells from H2O2-induced cell death. Am J Respir Cell Mol Biol 2003; 29(4): 513.
26. Klein C, Wustefeld T, Heinrich PC, et al. ME3738 protects from concanavalin A-induced liver failure via an IL-6-dependent mechanism. Eur J Immunol 2003; 33(8): 2251.
27. Wang CY, Mayo MW, Korneluk RG, et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998; 281(5383): 1680.
28. Deveraux QL, Reed JC. IAP family proteins: suppressors of apoptosis. Genes Dev 1999; 13(3): 239.
29. Stroka DM, Badrichani AZ, Bach FH, et al. Overexpression of A1, an NF-kappaB-inducible anti-apoptotic bel gene, inhibits endothelial cell activation. Blood 1999; 93(11): 3803.
30. Hillebrands JL, Klatter FA, van den Hurk BM, et al. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001; 107(11): 1411.